Robeco Institutional Asset Management B.V. Sells 5,179 Shares of Incyte Co. (NASDAQ:INCY)

Robeco Institutional Asset Management B.V. lowered its holdings in shares of Incyte Co. (NASDAQ:INCY) by 0.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,260,787 shares of the biopharmaceutical company’s stock after selling 5,179 shares during the quarter. Robeco Institutional Asset Management B.V. owned about 0.65% of Incyte worth $87,083,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. R Squared Ltd bought a new stake in Incyte during the fourth quarter worth approximately $30,000. VCI Wealth Management LLC acquired a new stake in shares of Incyte in the fourth quarter worth $1,025,000. Union Bancaire Privee UBP SA bought a new stake in shares of Incyte during the 4th quarter worth $311,000. Blue Trust Inc. grew its stake in Incyte by 124.6% in the 4th quarter. Blue Trust Inc. now owns 593 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 329 shares during the last quarter. Finally, Patton Albertson Miller Group LLC raised its holdings in Incyte by 10.9% in the 4th quarter. Patton Albertson Miller Group LLC now owns 87,329 shares of the biopharmaceutical company’s stock worth $6,032,000 after acquiring an additional 8,586 shares during the period. Institutional investors and hedge funds own 96.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on INCY. Morgan Stanley raised their target price on Incyte from $64.00 to $69.00 and gave the company an “equal weight” rating in a report on Wednesday, October 30th. Oppenheimer boosted their price target on Incyte from $81.00 to $82.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. BMO Capital Markets reiterated an “underperform” rating and issued a $52.00 price objective (up previously from $48.00) on shares of Incyte in a research report on Wednesday, October 30th. StockNews.com cut Incyte from a “strong-buy” rating to a “buy” rating in a research report on Friday, December 13th. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of Incyte in a research note on Friday, January 10th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, Incyte currently has an average rating of “Hold” and an average target price of $75.71.

Insider Buying and Selling

In other Incyte news, insider Thomas Tray sold 650 shares of Incyte stock in a transaction on Friday, December 13th. The shares were sold at an average price of $70.64, for a total transaction of $45,916.00. Following the completion of the sale, the insider now owns 23,962 shares of the company’s stock, valued at approximately $1,692,675.68. The trade was a 2.64 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Barry P. Flannelly sold 3,680 shares of the stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $79.68, for a total value of $293,222.40. Following the completion of the transaction, the executive vice president now directly owns 58,042 shares in the company, valued at $4,624,786.56. The trade was a 5.96 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 23,375 shares of company stock worth $1,737,578 over the last three months. 17.60% of the stock is currently owned by company insiders.

Incyte Stock Up 0.8 %

Shares of NASDAQ INCY opened at $73.72 on Thursday. Incyte Co. has a 12-month low of $50.35 and a 12-month high of $83.95. The firm’s 50-day simple moving average is $71.66 and its 200 day simple moving average is $68.68. The company has a quick ratio of 1.82, a current ratio of 1.87 and a debt-to-equity ratio of 0.01. The company has a market cap of $14.20 billion, a price-to-earnings ratio of 526.61, a price-to-earnings-growth ratio of 0.53 and a beta of 0.71.

Incyte (NASDAQ:INCY) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.07 EPS for the quarter, missing the consensus estimate of $1.19 by ($0.12). Incyte had a net margin of 0.80% and a negative return on equity of 0.63%. The company had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.08 billion. During the same period last year, the company earned $0.91 earnings per share. Incyte’s revenue for the quarter was up 23.8% compared to the same quarter last year. On average, research analysts expect that Incyte Co. will post 0.39 earnings per share for the current fiscal year.

Incyte Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.